NASDAQ:GLUE Monte Rosa Therapeutics (GLUE) Stock Price, News & Analysis $19.17 -0.03 (-0.16%) Closing price 05/27/2026 04:00 PM EasternExtended Trading$19.30 +0.13 (+0.68%) As of 05/27/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Monte Rosa Therapeutics Stock (NASDAQ:GLUE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get GLUE alerts:Sign Up Key Stats Today's Range$19.08▼$20.1150-Day Range$14.72▼$20.9852-Week Range$3.90▼$25.77Volume571,374 shsAverage Volume694,589 shsMarket Capitalization$1.62 billionP/E RatioN/ADividend YieldN/APrice Target$32.50Consensus RatingModerate Buy Company Overview Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden. The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience. In immuno-oncology, Monte Rosa applies its platform to better understand tumor microenvironments and to design molecules that modulate immune cell activity. In neuroscience, the company focuses on identifying targets implicated in neurodegenerative and neuroinflammatory disorders. Through this dual therapeutic focus, Monte Rosa seeks to advance candidates from early discovery through lead optimization and into partnerships or further development stages. Monte Rosa operates at the intersection of technology and biology, collaborating with academic institutions and industry partners to validate its discoveries and expand its library of therapeutic assets. The company is led by a team of experienced executives and scientists with backgrounds in genomics, AI, drug development and venture financing. While primarily based in the United States, Monte Rosa’s platform and partnerships enable it to engage with global research networks and to pursue programs with worldwide impact.AI Generated. May Contain Errors. Read More Monte Rosa Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreGLUE MarketRank™: Monte Rosa Therapeutics scored higher than 42% of companies evaluated by MarketBeat, and ranked 653rd out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingMonte Rosa Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 7 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialMonte Rosa Therapeutics has a consensus price target of $32.50, representing about 69.5% upside from its current price of $19.17.Amount of Analyst CoverageMonte Rosa Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Monte Rosa Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Monte Rosa Therapeutics are expected to decrease in the coming year, from ($1.23) to ($1.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Monte Rosa Therapeutics is -12.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Monte Rosa Therapeutics is -12.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMonte Rosa Therapeutics has a P/B Ratio of 3.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Monte Rosa Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.92% of the float of Monte Rosa Therapeutics has been sold short.Short Interest Ratio / Days to CoverMonte Rosa Therapeutics has a short interest ratio ("days to cover") of 20.63, which indicates bearish sentiment.Change versus previous monthShort interest in Monte Rosa Therapeutics has recently decreased by 1.19%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMonte Rosa Therapeutics does not currently pay a dividend.Dividend GrowthMonte Rosa Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Monte Rosa Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for GLUE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Monte Rosa Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Monte Rosa Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $668,694.00 in company stock.Percentage Held by Insiders6.40% of the stock of Monte Rosa Therapeutics is held by insiders.Percentage Held by Institutions79.96% of the stock of Monte Rosa Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Monte Rosa Therapeutics' insider trading history. Receive GLUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Monte Rosa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GLUE Stock News HeadlinesPiper Sandler Sticks to Their Buy Rating for Monte Rosa Therapeutics (GLUE)May 22, 2026 | theglobeandmail.comMonte Rosa Therapeutics to Participate in Upcoming Investor ConferencesMay 20, 2026 | globenewswire.comMassive Data Leak Exposes 512,000-Line Code That Could Change Society Forever"You won't believe what I discovered at 4 World Trade Center" When our financial media correspondent traveled to Lower Manhattan for a sit-down interview with 60-year Wall Street legend Marc Chaikin, she was shocked to discover that Marc had prepared a live demonstration of a technology that could change society forever. It involves NASA, the Department of Defense, huge banks – and a MAJOR AI upgrade that could add $400 trillion to the global economy. | Chaikin Analytics (Ad)Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives $32.50 Average PT from BrokeragesMay 19, 2026 | americanbankingnews.comMonte Rosa Trial Progress And Valuation Gap Draw Investor AttentionMay 11, 2026 | finance.yahoo.comMonte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business UpdatesMay 7, 2026 | globenewswire.comMonte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 5, 2026 | globenewswire.comMonte Rosa Therapeutics, Inc. (GLUE) Presents at AACR Annual Meeting 2026 - SlideshowApril 23, 2026 | seekingalpha.comSee More Headlines GLUE Stock Analysis - Frequently Asked Questions How have GLUE shares performed this year? Monte Rosa Therapeutics' stock was trading at $15.68 at the start of the year. Since then, GLUE stock has increased by 22.3% and is now trading at $19.17. How were Monte Rosa Therapeutics' earnings last quarter? Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) issued its quarterly earnings results on Thursday, May, 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by $0.06. The company had revenue of $4.21 million for the quarter, compared to the consensus estimate of $10.95 million. Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative trailing twelve-month return on equity of 40.99%. When did Monte Rosa Therapeutics IPO? Monte Rosa Therapeutics (GLUE) raised $211 million in an initial public offering (IPO) on Wednesday, June 23rd 2021. The company issued 11,700,000 shares at $17.00-$19.00 per share. Who are Monte Rosa Therapeutics' major shareholders? Top institutional investors of Monte Rosa Therapeutics include Versant Venture Management LLC (3.77%), Dimensional Fund Advisors LP (1.23%), Janus Henderson Group PLC (0.81%) and Arrowstreet Capital Limited Partnership (0.77%). Insiders that own company stock include Versant Venture Capital Vi, L, Markus Warmuth, Philip Nickson, Edmund Dunn and Chandra P Leo. View institutional ownership trends. How do I buy shares of Monte Rosa Therapeutics? Shares of GLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Monte Rosa Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Monte Rosa Therapeutics investors own include AUO (AUOTY), Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings5/07/2026Today5/28/2026Jefferies Global Healthcare Conference 20266/04/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (8m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 GLUE's financial health is in the Green zone, according to TradeSmith. GLUE has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GLUE CIK1826457 Webwww.monterosatx.com Phone617-949-2643FaxN/AEmployees90Year Founded2018Price Target and Rating Average Price Target for Monte Rosa Therapeutics$32.50 High Price Target$37.00 Low Price Target$29.00 Potential Upside/Downside+69.5%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$38.63 million Net Margins-302.69% Pretax Margin-307.04% Return on Equity-40.99% Return on Assets-25.94% Debt Debt-to-Equity RatioN/A Current Ratio9.54 Quick Ratio9.54 Sales & Book Value Annual Sales$123.67 million Price / Sales13.10 Cash FlowN/A Price / Cash FlowN/A Book Value$6.18 per share Price / Book3.10Miscellaneous Outstanding Shares84,480,000Free Float79,072,000Market Cap$1.62 billion OptionableOptionable Beta1.62 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:GLUE) was last updated on 5/28/2026 by MarketBeat.com Staff. From Our PartnersHow to claim a stake in SpaceX before the June 12 IPOSpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...Brownstone Research | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredThe SpaceX hype is real. So is what happens after.SpaceX just filed for what could be a $2 trillion IPO, with the roadshow starting in June. History shows that ...Americas Gold Company | SponsoredMassive Data Leak Exposes 512,000-Line Code That Could Change Society Forever"You won't believe what I discovered at 4 World Trade Center" When our financial media correspondent travel...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredA 25,000% opportunityAngel investor Jason Calacanis - who made a fortune on an early Uber stake - says Elon Musk's latest project c...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monte Rosa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monte Rosa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
